Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
about
Supramaximal dose of candesartan in proteinuric renal diseaseAntihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemMonitoring kidney function and albuminuria in patients with diabetes.Comparing angiotensin II receptor blockers on benefits beyond blood pressureAngiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials.Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trialEndothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination.Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney DiseaseRetarding the progression of chronic kidney disease with renin angiotensin system blockadePrevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markersRenin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Pharmacological management of renal fibrotic disease.Comprehensive approach to diabetic nephropathy.Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelinesPreparing for the worst while hoping for the best: the relevance of hope in the heart failure illness trajectory.The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome.Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.High dose Losartan and ACE gene polymorphism in IgA nephritis.Cardiovascular disease in chronic kidney disease.Clinical implications of the change in glomerular filtration rate with adrenergic blockers in patients with morning hypertension: the Japan morning surge-1 study.Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. Commentary.Application of direct renin inhibition to chronic kidney disease.Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives.Direct renin inhibition in chronic kidney disease.The effect of RAAS blockade on the progression of diabetic nephropathy.A review of chemical therapies for treating diabetic hypertension.Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.The role of urate and xanthine oxidase in vascular oxidative stress: future directions.Blockade of the renin-angiotensin system for renal protection: from history to future perspectives.Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study.Drugs with blocking effects on the renin-angiotensin-aldosterone system do not improve endothelial dysfunction long-term in hypertensive patients.Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
P2860
Q24649685-E563D9EC-EC0E-410A-8A00-EAE79EDC49D1Q26865691-6C8E5B3E-C10F-4E67-A2A5-051B5C89A223Q27691297-DA175324-ECDD-4A1F-8189-D01E4A860D86Q30360678-03679AE5-144F-4A30-97D1-F891A368527FQ35111064-C8B21BBA-5FF6-4514-A601-CCB96AB0A109Q35128415-D58E2B6A-00D4-4574-8B02-13555CFD96B3Q35210505-5CBECE13-65C3-47EF-8396-EEB5126FB2A7Q35546994-7A7A574F-A5CC-4CAB-ADF8-DA5223D74863Q35914820-D086AB1F-D996-478D-8FBB-B9D3DC348D0DQ36082302-A15C7749-0143-45A8-8633-8286359D028BQ36094286-CE741742-613F-49E3-B509-36D5D96B6BF0Q36125465-AEDE6ACA-153B-478D-A636-4E7AD6603092Q36329456-B7F4B344-95AB-438F-A16E-AAA69DE2180DQ36407348-ED2D8617-D582-4F91-8947-A2B850F26A7EQ36466019-A192B98C-63D6-4B47-8243-8D3655837583Q36675396-F7F2A35D-3D56-4BD3-808B-D7452A52BB23Q36701736-0A9B0D44-CE93-4C78-AA77-126A3C025C21Q36834059-6AAC7AE3-2BF0-4E2A-A13B-CD5066BC6794Q36839029-D8063B64-9EA3-4FCF-8656-3AEBFC178214Q36901526-F43E3B9D-4555-4F54-998B-258782C689BAQ37159292-DD316CED-E37F-422B-A6D6-916B74EA304AQ37167598-4526EC66-9F81-4584-B595-A6DCD1D6901CQ37223733-F2F726F2-0842-4B9F-9B6F-FC9A61141FFEQ37362775-A2539AF7-634F-49EF-981C-076A11002F51Q37394725-EDD50685-62DE-44CE-8E03-FF691CFF50B8Q37574913-1B7339A0-4DDF-434B-BD4E-7AA2CCEE98DEQ37702747-47AA9954-7AFA-49B3-A371-777B0D6AFFF8Q37758534-992132D6-BE3E-4472-8752-15510C4D3DD8Q37959062-A4F17EF9-96ED-473E-8403-B6200CC5B65EQ38070781-5E72E248-345F-4A68-8657-1D72C1EEE28DQ38168046-E543779E-15AD-4F2E-ACB6-B65C11BEDAE5Q39290260-F9D77B75-99C2-4585-9E98-48B0E5609EA5Q39631863-A8D0F9E4-73AD-4731-B284-AFA6501521C9Q39936328-038CFA50-B0C1-4BA1-B17B-15D5987B7533Q40133091-99D47A3D-EF70-4ED8-B718-3507C070F461Q41998504-ED8B72BF-A929-446F-89A4-60C207F4138CQ42945846-F2007560-1A69-41EC-98BA-B27913189DA9Q43275293-634107C6-63B0-4CDE-A511-D58327E1BBF1Q44474346-F939C8A5-8D8D-4A9D-8B7F-823FB4717076Q46115914-41CC8C16-7454-4997-8AF4-11E4A9C2C627
P2860
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Enhanced renoprotective effect ...... diabetes and microalbuminuria.
@en
Enhanced renoprotective effect ...... diabetes and microalbuminuria.
@nl
type
label
Enhanced renoprotective effect ...... diabetes and microalbuminuria.
@en
Enhanced renoprotective effect ...... diabetes and microalbuminuria.
@nl
prefLabel
Enhanced renoprotective effect ...... diabetes and microalbuminuria.
@en
Enhanced renoprotective effect ...... diabetes and microalbuminuria.
@nl
P2093
P1433
P1476
Enhanced renoprotective effect ...... diabetes and microalbuminuria.
@en
P2093
Berit R Jensen
Frans Boomsma
Hans-Henrik Parving
Kasper Rossing
Katrine J Schjoedt
P304
P356
10.1111/J.1523-1755.2005.00511.X
P407
P577
2005-09-01T00:00:00Z
P5875
P6179
1053471411